Year: 2020
Type: article
Abstract: Head and neck squamous cell carcinoma (HNSCC) lacks predictive biomarkers for drug responses. By targeted sequencing, we identified two MAPK1 mutations in recurrent HNSCC, MAPK1p.D321N, and p.R135K. We previously reported an exceptional erlotinib responder with MAPK1p.E322K. Here, by in silico and drug studies, we determined functions of these two recurrence-associated MAPK1 mutations. Residues D321, R135, and E322 are in 3D proximity. MAPK1p.D321N drives marked in vivo erlotinib sensitivity, while p.R135K’s effect is moderate.
Source: npj Genomic Medicine
Authors: Hoi-Lam Ngan, Peony Hiu Yan Poon, Yu-Xiong Su, Jason Ying Kuen Chan, Kwok-Wai Lo, Chun Kit Yeung, Yuchen Liu, Eileen Wong, Hui Li, Chin Wang Lau, Wenying Piao, Vivian Wai Yan Lui
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,290
Funders: U.S. Department of Health and Human Services, Impact Fund, Research Grants Council, University Grants Committee, Chinese University of Hong Kong, Food and Health Bureau, Innovation and Technology Fund, Hong Kong Cancer Fund, Hong Kong Government, National Institutes of Health, Health and Medical Research Fund, National Cancer Institute
Awards: G1300084006, RAC1 Genomic Alterations Drive Head and Neck Cancer Progression, G1634204228, A multicenter evaluation of a combination of nasopharyngeal brush biopsy and plasma for EBV DNA in detecting local failures in nasopharyngeal carcinoma., G2231019772, Estrogen receptor alpha induces autophagy and heme oxygenase-1 in human papillary thyroid cancer cells, MAPK1 Genomic Alterations as Predictor of Treatment Response and Driver for Tumor Growth in Head and Neck Cancer, G4104336979, Novel microneedle array loaded with anti-PD-1-cisplatin-nanoparticles for synergistic cancer immuno-chemotherapy, qHTS of Patient Derived HCC Models to Identify Novel Probes/Therapeutic Agents, G4971294347, G5500127613, ALK/PIK3CA Genetic Coupling: Implications for Progression and Personalized Therapy in Head and Neck Cancer, G619793188, G6873039078, G7152321723
OpenAlex ID: W3016407441